|
|
Blood, 15 November 2003, Vol. 102, No. 10, pp. 3514-3520.
Prepublished online as a Blood First Edition Paper on July 31, 2003; DOI 10.1182/blood-2003-01-0055.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
Iman Jilani,
Susan O'Brien,
Taghi Manshuri,
Deborah A. Thomas,
Vilmos A. Thomazy,
Maha Imam,
Sana Naeem,
Srdan Verstovsek,
Hagop Kantarjian,
Francis Giles,
Michael Keating, and
Maher Albitar
From the Departments of Hematopathology and Leukemia, University of Texas MD Anderson Cancer Center, Houston.
Lymphoid cells in most patients with chronic lymphocytic leukemia (CLL), when treated with rituximab, become CD20-. This is thought to be due to masking of CD20 by rituximab. We used specific antimouse immunoglobulin antibodies to detect rituximab on the surface of CLL lymphocytes and we demonstrate that rituximab is rarely detectable after therapy. Only 3 of 65 patients with CLL had rituximab detectable on their lymphocytes after rituximab therapy despite the fact that most had no detectable CD20 expression. In vitro mixing of CLL or Raji cells with rituximab demonstrated that rituximab was detectable on the surface of cells due to its binding to CD20. However, the addition of plasma led to the down-modulation of CD20 expression, and the rituximab became undetectable. This down-modulation of CD20 protein expression was associated with a down-modulation of CD20 mRNA. CLL cells that lost their CD20 expression regained CD20 expression after 24 hours in culture. These data suggest that rituximab therapy leads to a substantial but transient down-modulation of CD20 expression and that negativity for CD20 in cells from patients treated with rituximab is not necessarily due to CD20 masking. The importance of this down-modulation in the efficacy of current therapy with rituximab needs further investigation. (Blood. 2003;102: 3514-3520)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Apparent modulation of CD20 by rituximab: an alternative explanation
- Mark S. Cragg, Mike C. Bayne, Timothy M. Illidge, Thomas Valerius, Peter W. N. Johnson, Martin J. Glennie, Iman Jilani, and Maher Albitar
Blood 2004 103: 3989-3991.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. J. Leandro, N. Cooper, G. Cambridge, M. R. Ehrenstein, and J. C. W. Edwards
Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy
Rheumatology,
January 1, 2007;
46(1):
29 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K N Naresh, I Lampert, R Hasserjian, D Lykidis, K Elderfield, D Horncastle, N Smith, W Murray-Brown, and G W Stamp
Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol.
J. Clin. Pathol.,
September 1, 2006;
59(9):
903 - 911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman, J. H. N. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al.
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
J. Immunol.,
July 1, 2006;
177(1):
362 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Bubien, H.-L. Ji, G. Y. Gillespie, C. M. Fuller, J. M. Markert, T. B. Mapstone, and D. J. Benos
Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1
Am J Physiol Cell Physiol,
November 1, 2004;
287(5):
C1282 - C1291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Cragg, M. B. Bayne, A. L. Tutt, R. R. French, S. Beers, M. J. Glennie, and T. M. Illidge
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
Blood,
October 15, 2004;
104(8):
2540 - 2542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Teeling, R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. H. I. Parren, C. E. Hack, M. Dechant, et al.
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Blood,
September 15, 2004;
104(6):
1793 - 1800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Cragg, M. C. Bayne, T. M. Illidge, T. Valerius, P. W. N. Johnson, M. J. Glennie, I. Jilani, and M. Albitar
Apparent modulation of CD20 by rituximab: an alternative explanation
Blood,
May 15, 2004;
103(10):
3989 - 3991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Tai, L. P. Catley, C. S. Mitsiades, R. Burger, K. Podar, R. Shringpaure, T. Hideshima, D. Chauhan, M. Hamasaki, K. Ishitsuka, et al.
Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
Cancer Res.,
April 15, 2004;
64(8):
2846 - 2852.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
